Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dissecting Piramal’s Damages Award In Sensipar Case

Executive Summary

A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.

You may also be interested in...



Dr Reddy’s Enters Complicated Sensipar Market In US

Dr Reddy’s Laboratories has launched a generic version of Sensipar in the US, the former blockbuster to treat hyperparathyroidism, with originator Amgen having previously been involved in multiple intellectual property fights over agreements with ANDA sponsors Teva and Cipla.

Cipla And Amgen Agree To Settle On Sensipar

Cipla launched its generic version of Amgen’s Sensipar ‘at risk’ in March last year after suing the originator and Teva over an earlier agreement between the pair. The suit has now been settled, although claims against Teva remain standing.

Piramal’s Sensipar Generic Blocked In US, For Now

Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel